Baird Initiates Coverage On Mereo BioPharma Group with Outperform Rating, Announces Price Target of $8
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Jack Allen has initiated coverage on Mereo BioPharma Group (NASDAQ:MREO) with an Outperform rating and a price target of $8.
June 13, 2024 | 9:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Jack Allen has initiated coverage on Mereo BioPharma Group with an Outperform rating and a price target of $8.
The initiation of coverage with an Outperform rating and a price target of $8 by a reputable analyst is likely to positively impact Mereo BioPharma Group's stock price in the short term. This rating suggests confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100